Download PDF
Thromb Haemost 1972; 28(02): 280-288
DOI: 10.1055/s-0038-1649093
Original Article
Schattauer GmbH

Coagulation Changes Induced by Endotoxin and Purified Contact Activation Product

P Barth
1   Medical Department of the University of Heidelberg (Ludolf-Krehi-Klinik) (Head: Prof. Dr. G. Schettler)
,
R Zimmermann
1   Medical Department of the University of Heidelberg (Ludolf-Krehi-Klinik) (Head: Prof. Dr. G. Schettler)
› Author Affiliations
Further Information

Publication History

Publication Date:
29 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

By use of purified contact activation product (CAP) it was possible to show that activation of the contact phase of the coagulation system can lead to a state of hypo-coagulability very similar to that occurring in the experimental Sanarelli-Shwartz-man phenomenon (SSP). The coagulation changes which occurred suggested that the difference between the effects of CAP administration and the typical experimental SSP appeared to be merely quantitative in nature. However, the fact that in our experiments on the classical SSP no stasis thrombi developed as the most significant sign of increased coagulation activity, may suggest that pathogenetically important differences exist.

 

  • References

  • 1 Alexander B, Kliman A, Colman R, Scholtz E, and De Francesco A. 1959. New hemophiloid defects. Some clinicolaboratory and experimental abnormalities in thromboplastin generation. In: Brinkhous K. M, and De Nicola P. (eds.) Hemophilia and other hemorrhagic states. University of North Carolina Press; Chapel Hill.: 137.
    Search in Google Scholar
  • 2 Ashkinazi I. Y, Klemina I. K. 1970; The influence of activated Hageman factor on the blood coagulation system in vivo. (Russ.). Byulleten Eksperimental’noi Biologui mediciny 69 (04) 32.
    PubMedSearch in Google Scholar
  • 3 Barth P, Kommerell B, and Pfleiderer Th. 1966; The effect of the contact factors of the coagulation system on platelet aggregation. Thrombosis et Diathesis Haemorrhagica 16: 378.
    PubMedSearch in Google Scholar
  • 4 Barth P, and Kommerell B. 1969; Isolierung des Kontaktaktivierungsproduktes des Gerinnungssystems aus Schweineplasma. Thrombosis et Diathesis Haemorrhagica 21: 500.
    PubMedSearch in Google Scholar
  • 5 Barth P, Kommerell B, and Oswald M. 1969; Über einen Einstufentest zur Bestimmung des Kontaktaktivierungsproduktes des Gerinnungssystems. Thrombosis et Diathesis Haemorrhagica 21: 508.
    PubMedSearch in Google Scholar
  • 6 Barth P, Fritsch H, Immich H, Kommerell B, and Marti H. 1970; Purified contact activation product of the coagulation system in experimental thrombosis. Atherosclerosis 12: 225.
    CrossrefPubMedSearch in Google Scholar
  • 7 Botti R. E, and Ratnoff O. D. 1964; Studies on the pathogenesis of thrombosis. An experimental hypercoagulable state induced by the intravenous injection of ellagic acid. Journal of Laboratory and Clinical Medicine 64: 384.
    PubMedSearch in Google Scholar
  • 8 Clattss A. 1957; Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematologica 17: 237.
    CrossrefPubMedSearch in Google Scholar
  • 9 Dahlmann W. 1967 Über eine neue Methode zur Bestimmung des Faktors VIII. Thesis, Bonn.
    PubMedSearch in Google Scholar
  • 10 Feissly R, and Lüdin U. 1949; Microscopie par contacts de phase. Revue d’hematologie 4: 481.
    PubMedSearch in Google Scholar
  • 11 Hartert H. 1948; Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren. Klinische Wochenschrift 26: 577.
    CrossrefPubMedSearch in Google Scholar
  • 12 Henderson E. S, and Rapaport S. J. 1962; The thrombotic activity of activation product. Journal of Clinical Investigation 41: 235.
    CrossrefPubMedSearch in Google Scholar
  • 13 Iatridis S. G. 1966; Ellagic acid-induced acceleration of intravascular clotting and thrombolysis. Hemostase 6: 363.
    PubMedSearch in Google Scholar
  • 14 Koller F, Loeliger H, and Duckest F. 1951; Experiments on a new clotting factor. Acta Haematologica 6: 1.
    CrossrefPubMedSearch in Google Scholar
  • 15 Lasch H. G, Krecke H. J, Rodrigues-Erdmann F, Sessner H. H, and Schütterle G. 1961; Verbrauchskoagulopathien (Pathogenese und Therapie). Folia Haematologica (Neue Folge) 6: 325.
    PubMedSearch in Google Scholar
  • 16 Lasch H. G, Heene D. L, Huth H, and Sandritter W. 1967; Pathophysiology, clinical manifestation and therapy of consumption-coagulopathy (‘Verbrauchskoagulopathie’). American Journal of Cardiology 20: 381.
    CrossrefPubMedSearch in Google Scholar
  • 17 Mammen E. F, and Grammens G. The purification and some properties of bovine Hageman Factor. Thrombosis et Diathesis Haemorrhagica 18: 306.
    PubMed
  • 18 McKay D. G, Müller-Berghaus G, and Cruse B. A. 1969; Activation of Hageman factor by ellagic acid and the generalized Shwartzman Reaction. American Journal of Pathology 54: 393.
    PubMedSearch in Google Scholar
  • 19 Müller-Berghaus G, and Lasch H.-G. 1970; Consumption of Hageman Factor activity in the generalized Shwartzman Reaction induced by Liquoid. Thrombosis et Diathesis Haemorrhagica 23: 386.
    PubMedSearch in Google Scholar
  • 20 Müller-Berghaus G, and Lasch H. G. 1970; Aktivitätsänderung des Hageman-Faktors nach intravenöser Liquoidinjektion bei mit Cumarin vorbehandelten Kaninchen. Verhandlungen der Deutschen Gesellschaft für innere Medizin 76: 594.
    PubMedSearch in Google Scholar
  • 21 Nossel H. L. and Niemetz 1965; A normal inhibitor of the blood coagulation contact reaction product. Blood 25: 712.
    PubMedSearch in Google Scholar
  • 22 Ratnoff O. D. 1958; An enzyme in plasma inactivating Hageman Factor. Journal of Clinical Investigation 37: 923.
    PubMedSearch in Google Scholar
  • 23 Schnebergee R, and Müller-Berghaus G. 1970; Verhalten der Hageman-Faktor-Aktivität nach intravenöser Endotoxininjektion bei mit Cumarin vorbehandelten Kaninchen. Verhandlungen der Deutschen Gesellschaft für innere Medizin 76: 597.
    PubMedSearch in Google Scholar
  • 24 Schneider C. L. 1951; “Fibrin embolism” (Disseminated intravascular coagulation) with defibrination as one of the end results during placenta abruptio. Surgery, Gynecology and Obstetrics with International Abstracts of Surgery 92: 27.
    PubMedSearch in Google Scholar
  • 25 Thomas D. P, and Wessler S. 1964; Stasis thrombi induced by bacterial endotoxin. Circulation Research 14: 486.
    CrossrefPubMedSearch in Google Scholar
  • 26 Thomas D. P, Wessler S, and Reimer S. M. 1962; The relationship of activated Factor XII (Hageman) and bacterial endotoxin to hypercoagulability. Federation Proceedings 21: 61.
    PubMedSearch in Google Scholar
  • 27 Wessler S. 1952; Coagulation changes in isolated venous segments of the dog. Journal of Clinical Investigation 31: 672.
    PubMedSearch in Google Scholar
  • 28 Wessler S, and Reimer S. M. 1960; The role of human coagulation factors in serum induced thrombosis. Journal of Clinical Investigation 39: 262.
    CrossrefPubMedSearch in Google Scholar
  • 29 Wessler S, Yin E. T, Caston L. W, and Nicol I. 1967; A distinction between the precursor and activated forms of clotting factors in the genesis of stasis thrombi. Thrombosis et Diathesis Haemorrhagica 18: 12.
    PubMedSearch in Google Scholar